Increased oxidative stress condition found in different stages of HIV disease in patients undergoing antiretroviral therapy in Umuahia (Nigeria)

Immunopharmacology and Immunotoxicology

Volumn 34, Issue 6, 2012, Pages 1060-1066

  Ibeh, Bartholomew Okechukwu ^a   Emeka Nwabunnia, Ijeoma Kalu ^b  

^a MICHAEL OKPARA UNIVERSITY OF AGRICULTURE   (Nigeria)

^b Department of Biotechnology   (Nigeria)

Author keywords

AIDS; Antiretroviral; Heterosexual; HIV; MDA; Nigeria; Oxidative stress

Indexed keywords

BIOLOGICAL MARKER; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; MALONALDEHYDE;

ADULT; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONCENTRATION (PARAMETERS); CYTOMETRY; DISEASE COURSE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; NIGERIA; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING; SPECTROPHOTOMETRY; TREATMENT DURATION;

ADULT; ANTIOXIDANTS; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MALONDIALDEHYDE; MIDDLE AGED; NIGERIA; OXIDATIVE STRESS; T-LYMPHOCYTES;

EID: 84868124896     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2012.681327     Document Type: Article

References (49)

1. Kellog, E.W., Fridovich, J. Liposome oxidation and erythrocytes lysis by enzymatically generated superoxide and hydrogen peroxide. J Biol Chem 1977, 252, 6721-6728.
2. Kellog, E.W., Fridovich, J. Superoxide, hydrogen peroxide and singlet oxygen in lipid peroxidation by xanthine oxidase system. J Biol Chem 1975, 250, 8812-8817.
3. Aruoma, O.I. Free radicals in tropical diseases. London: Harwood. Life Sciences 1993, 18:5-8.
4. Farmer, E.E., Davoine, C. Reactive electrophile species. Curr Opin Plant Biol 2007, 10, 380-386.
5. Del Rio, D., Stewart, A.J., Pellegrini, N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis 2005, 15, 316-328.
6. Moore, K., Roberts, L.J., 2nd. Measurement of lipid peroxidation. Free Radic Res 1998, 28, 659-671.
7. Wong, G.H., McHugh, T., Weber, R., Goeddel, D.V. Tumor necrosis factor a selectively sensitizes human immunodeficiency virusinfected cells to heat and radiation. Proc Natl Acad Sci USA 1991, 88, 4372-4376.
8. Aukrust, P., Muler, F., Svardal, A.M., Ueland, T., Berge, R.K., Fr?and, S.S. Disturbed glutathione metabolism and decreased antioxidant levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapyYpotential immunomodulatory effects of antioxidants. J Infect Dis 2003, 188, 232-238.
9. Hulgan, T., Morrow, J., Aguila, R., Raffanti, S., Morgan, M., Rebeiro, P. Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clin Infect Dis 2003, 37, 1711-1717.
10. Westendorp, M.O., Shatrov, V.A., Schulze-Osthoff, K., Frank, R., Kraft, M., Los, M., Krammer, P.H., Dr?e, W., Lehmann, V. HIV-1 Tat potentiates TNF-induced NF-κ B activation and cytotoxicity by altering the cellular redox state. EMBO J 1995, 14, 546-554.
11. Schreck, R., Rieber, P., Baeuerle, P.A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κ B transcription factor and HIV-1. EMBO J 1991, 10, 2247-2258.
12. Das, U.N., Padma, M., Sagar, P.S., Ramesh, G., Koratkar, R. Stimulation of free radical generation in human leukocytes by various agents including tumor necrosis factor is a calmodulin dependent process. Biochem Biophys Res Commun 1990, 167, 1030-1036.
13. McCord, J.M. The superoxide free radical: its biochemistry and pathophysiology. Surgery 1983, 94, 412-414.
14. Freeman, B.A., Crapo, J.D. Biology of disease: free radicals and tissue injury. Lab Invest 1982, 47, 412-426.
15. Halliwell, B. Oxidants and human disease: some new concepts. FASEB J 1987, 1, 358-364.
16. Grabar, S., Le Moing, V., Goujard, C., Leport, C., Kazatchkine, M.D., Costagliola, D., Weiss, L. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000, 133, 401-410.
17. Cossarizza, A., Moyle, G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 2004, 18, 137-151.
18. de La Asunci?n, J., del Olmo, M.L., Sastre, J.A., Mill?, A., Pell?, A., Pallardu F . V., Vi?, J. AZT treatment induces molecular and ultra structural oxidative damage to muscle mitochondria: prevention by antioxidant vitamins. J Cli Invest 1998, 102, 4-9.
19. Center for Disease Control and Prevention(CDC). Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1993, (RR-17), 1-19.
20. Wallin, B., Roseengren, B., Shetzer, H.G., Camego, G. Lipoprotein oxidation and measurement of thiobarbituric acid reacting substance (TBARS) formation in a single micro plate: its use for evaluation of antioxidants. Ann Biochem 1993, 208, 10-15.
21. WHO. (2010). Priority interventions; HIV/AIDS prevention, treatment and care in the health sector (2010 version). WHO publications. pp. 1-174. Available at: http://www.who.int/hiv/pub/guidelines/9789241500234/en/index.html. Accessed on March, 2011.
22. Ibeh, B.O., Obidoa, O., Uzoegwu, P.N. High plasma activity of endogenous antioxidants protect CD4+ T-cells in HIVserodiscordant heterosexual partners in a Nigerian population. Int J STD AIDS 2008, 19, 536-540.
23. Aquaro, S., Scopelliti, F., Pollicita, M., Perno, C.F. Oxidative stress and HIV infection: target pathways for novel therapies? Future HIV Therapy 2008, 2, 327-338. (DOI: 10.2217/17469600.2.4.327).
24. UNAIDS/WHO. (2007). Report on the Global AIDS Epidemic. Epidemic update. pp. 1-4. Available at: http://data.unaids. org/pub/epislides/2007/2007- epiupdate-en.pdf. Accessed on November, 2010.
25. Anafi, S.B., Muktarhm, D.F. Alawode, D.F. Commonly prescribed drugs in hiv/aids and patient's socio-demographic data: a case study of University of Ilorin teaching hospital (UITH), Ilorin, Nigeria. Nigerian J Pharm Sci 2008, 7, 139-145.
26. Mojumdar, K., Vajpayee, M., Chauhan, N.K., Singh, A., Singh, R., Kurapati, S. Loss of CD127 & increased immunosenescence of T cell subsets in HIV infected individuals. Indian J Med Res 2011, 134, 972-981.
27. Skowron, G., Spritzler, J.G., Weidler, J., Robbins, G.K., Johnson, V.A., Chan, E.S., Asmuth, D.M., Gandhi, R.T., Lie, Y., Bates, M., Pollard, R.B.; NIH/NIAID ACTG 384 Protocol Team and Monogram Biosciences. Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 2009, 50, 250-258.
28. Gandhi, R.T., Spritzler, J., Chan, E., Asmuth, D.M., Rodriguez, B., Merigan, T.C., Hirsch, M.S., Shafer, R.W., Robbins, G.K., Pollard, R.B.; ACTG 384 Team. Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 2006, 42, 426-434.
29. Knox, K.S., Vinton, C., Hage, C.A., Kohli, L.M., Twigg, H.L. 3rd., Klatt, N.R., Zwickl, B., Waltz, J., Goldman, M., Douek, D.C., Brenchley, J.M. Reconstitution of CD4 T cells in bronchoalveolar lavage fluid after initiation of highly active antiretroviral therapy. J Virol 2010, 84, 9010-9018.
30. Landay, A., da Silva, B.A., King, M.S., Albrecht, M., Benson, C., Eron, J., Glesby, M., Gulick, R., Hicks, C., Kessler, H., Murphy, R., Thompson, M., White, A.C. Jr., Wolfe, P., McMillan, F.I., Hanna, G.J. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis 2007, 44, 749-754.
31. Guihot, A., Dentone, C., Parizot, C., Tindel, M., Marcelin, A., Calvez, V., Costagliola, D., Katlama, C., Autran, B., Carcelain, G. CD4 nadir drives persistence of monocytes and T-lymphocytes activation in virologically suppressed HIV-infected patients. Boston, MA: 18th Conference on Retroviruses and Opportunistic Infections.February 27YMarch 2, 2011.
32. Aiuti, F., Mezzaroma, I. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART. AIDS Rev 2006, 8, 88-97.
33. Audigu A., Taffu P., Rickenbach, M., Battegay, M., Vernazza, P., Nadal, D., Speck, R.F. Swiss HIV Cohort Study (SHCS). 210 Low Post-Seroconversion CD4 Count and Rapid Decrease of CD4 Density Identify HIV+ Fast Progressors. JAIDS 2011, 56, 90.
34. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2011). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. pp. 1-167. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed on March 2012.
35. Cao, W., Jamieson, B.D., Hultin, L.E., Hultin, P.M., Effros, R.B., Detels, R. Premature aging of T cells is associated with faster HIV-1 disease progression. J Acquir Immune Defic Syndr 2009, 50, 137-147.
36. Cocchi, F., DeVico, A.L., Garzino-Demo, A., Arya, S.K., Gallo, R.C., Lusso, P. Identification of RANTES, MIP-1 a, and MIP-1 ß as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995, 270, 1811-1815.
37. Herbein, G., Varin, A. The macrophage in HIV-1 infection: from activation to deactivation? Retrovirology 2010, 7, 33.
38. Lachgar, A., Bernard, J., Bizzini, B., Astgen, A., Le Coq, H., Fouchard, M., Chams, V., Feldman, M., Burny, A., Zagury, J.F. Repair of the in vitro HIV-1-induced immunosuppression and blockade of the generation of functional suppressive CD8 cells by anti-a interferon and anti-Tat antibodies. Biomed Pharmacother 1996, 50, 13-18.
39. Molloy, M.J., Zhang, W., Usherwood, E.J. Suppressive CD8+ T cells arise in the absence of CD4 help and compromise control of persistent virus. J Immunol 2011, 186, 6218-6226.
40. Smith, D.E., Walker, B.D., Cooper, D.A., Rosenberg, E.S., Kaldor, J.M. Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS 2004, 18, 709-718.
41. Ngondi, J.L., Oben, J., Forkah, D.M., Etame, L.H., Mbanya, D. The effect of different combination therapies on oxidative stress markers in HIV infected patients in Cameroon. AIDS Res Ther 2006, 3, 19.
42. Anthony, H., Kashou A.H., Agarwal A. Oxidants and Antioxidants in the Pathogenesis of HIV/AIDS. Open Reprod Sci J 2011, 3, 154-161.
43. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - A Working Group of the Office of AIDS Research Advisory Council (OARAC). (2008). Guidelines for the use of antiretroviral agents in HIV- 1-infected adults and adolescents. Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed on 15 February 2011.
44. Blankson, J.N. Primary HIV-1 infection: to treat or not to treat? AIDS Read 2005, 15, 245-6, 249.
45. Kassutto, S., Maghsoudi, K., Johnston, M.N., Robbins, G.K., Burgett, N.C., Sax, P.E., Cohen, D., Pae, E., Davis, B., Zachary, K., Basgoz, N., D'agata, E.M., DeGruttola, V., Walker, B.D., Rosenberg, E.S. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis 2006, 42, 1024-1031.
46. Strain, M.C., Little, S.J., Daar, E.S., Havlir, D.V., Gunthard, H.F., Lam, R.Y., Daly, O.A., Nguyen, J., Ignacio, C.C., Spina, C.A., Richman, D.D., Wong, J.K. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005, 191, 1410-1418.
47. Abdool Karim, S.S., Naidoo, K., Grobler, A., Padayatchi, N., Baxter, C., Gray, A., Gengiah, T., Nair, G., Bamber, S., Singh, A., Khan, M., Pienaar, J., El-Sadr, W., Friedland, G., Abdool Karim, Q. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010, 362, 697-706.
48. Wood, E., Hogg, R.S., Harrigan, P.R., Montaner, J.S. When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis 2005, 5, 407-414.
49. Jare?, E.J., Romu J., Romero, B., Mar?, N., Muriach, M., Johnsen, S., Bosch-Morell, F., Marselou, L., Romero, F.J. Serum malondialdehyde correlates with therapeutic efficiency of high activity antiretroviral therapies (HAART) in HIV-1 infected children. Free Radic Res 2002, 36, 341-344.